Table 3

Univariate analysis for the probability of achieving a complete cytogenetic response on imatinib by 3 months of therapy

ParameterEffectCCyR within 3 mo, median (range) or no. (%)
P
Yes (n = 143)No (n = 109)
Age, y NS 48 (15-79) 48 (17-84) .84 
Lower hemoglobin, g/dL Adverse 12.7 (8.8-16.7) 12 (6.2-15.1) < .001 
Higher WBC, ×109/L Adverse (trend) 24.5 (3.5-239.5) 35.8 (2.2-283) .06 
Platelets, ×109/L NS 372 (107-1476) 356 (100-1413) .71 
PB basophils, % NS 3 (0-19) 4 (0-19) .98 
Higher PB blasts, % Adverse 0 (0-3) 0 (0-12) < .001 
BM basophils, % NS 2 (0-8) 3 (0-15) .1 
Higher BM blasts, % Adverse 1 (0-13) 2 (0-14) .04 
Presence of splenomegaly Adverse 24 (17) 44 (41) < .001 
Presence of clonal evolution NS 4 (3) 3 (3) .99 
Longer CML duration, mo Adverse 0 (0-6) 1 (0-12) .06 
Dose (400 vs 800 mg/day) Adverse 18 (13) 31 (29) .001 
More than 90% Ph+ cells at start of therapy Adverse 130 (91) 104 (96) .09 
Sokal risk score     
    Low NS 105 (73) 57 (53) .83 
    Intermediate NS 33 (23) 34 (31) .83 
    High NS 5 (4) 17 (16) .83 
ParameterEffectCCyR within 3 mo, median (range) or no. (%)
P
Yes (n = 143)No (n = 109)
Age, y NS 48 (15-79) 48 (17-84) .84 
Lower hemoglobin, g/dL Adverse 12.7 (8.8-16.7) 12 (6.2-15.1) < .001 
Higher WBC, ×109/L Adverse (trend) 24.5 (3.5-239.5) 35.8 (2.2-283) .06 
Platelets, ×109/L NS 372 (107-1476) 356 (100-1413) .71 
PB basophils, % NS 3 (0-19) 4 (0-19) .98 
Higher PB blasts, % Adverse 0 (0-3) 0 (0-12) < .001 
BM basophils, % NS 2 (0-8) 3 (0-15) .1 
Higher BM blasts, % Adverse 1 (0-13) 2 (0-14) .04 
Presence of splenomegaly Adverse 24 (17) 44 (41) < .001 
Presence of clonal evolution NS 4 (3) 3 (3) .99 
Longer CML duration, mo Adverse 0 (0-6) 1 (0-12) .06 
Dose (400 vs 800 mg/day) Adverse 18 (13) 31 (29) .001 
More than 90% Ph+ cells at start of therapy Adverse 130 (91) 104 (96) .09 
Sokal risk score     
    Low NS 105 (73) 57 (53) .83 
    Intermediate NS 33 (23) 34 (31) .83 
    High NS 5 (4) 17 (16) .83 

NS indicates not significant.

View Large